SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Brad C. Dunlap who wrote (299)1/21/1997 11:35:00 PM
From: Webhead   of 1762
 
What do you all know about IDEC's patent position on it's PRIMATIZED antibody? The stock of protein design labs rocketed up when they received the patent for humanized monoclonals so I should think that IDEC may be sitting on a HUGE market offering competition to humanized monoclonals. IDEC already generates an impressive income from contract work constructing high producer cell lines. Imagine the royalites possible if they offered a viable alternative to humanized monoclonals and could sell the highly expressing cell lines!
Of course, the humanized patent may preclude "primatizing" antibodies since (I believe) the sequence of the primate used (macaque(sp?)) is identical to the human sequence in the altered region.

comments?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News